酪氨酸激酶抑制剂在慢性粒细胞白血病的应用及进展
Application and Progress of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
DOI: 10.12677/acm.2024.14102826, PDF,   
作者: 王慧娟：赣南医科大学第一临床医学院，江西 赣州；李海亮*：赣南医科大学第一附属医院血液内科，江西 赣州
关键词: 酪氨酸酶抑制剂；慢性粒细胞白血病；综述；Tyrosine Kinase Inhibitor； Chronic Myeloid Leukemia； Review
摘要: 慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤，简称慢粒。慢粒治疗应着重于慢性期早期，尽快获得细胞遗传学以及分子生物学水平的缓解，避免疾病转化，进入进展期的患者常常预后不佳。慢粒慢性期患者治疗首选酪氨酸激酶抑制剂(TKI)，TKI极大地改善了疾病地整体预后，使绝大多数患者生存期接近正常人。本文主要对TKI在CML的应用进展进行综述。
Abstract: CML is a malignant myeloproliferative tumor occurring in multifunctional hematopoietic stem cells, mainly involving the myeloid lineage. The treatment of CML should focus on the early chronic phase, avoid disease transformation, obtain cytogenetic and molecular remission as soon as possible. Once in the progressive phase, the patients may have a poor prognosis. TKI is the first choice for treatment in chronic patients. With the development of TKI, the course of CML has changed greatly, and the survival of most patients is close to normal people. This paper mainly reviews the application progress of TKI in CML.
文章引用：王慧娟, 李海亮. 酪氨酸激酶抑制剂在慢性粒细胞白血病的应用及进展[J]. 临床医学进展, 2024, 14(10): 1513-1520. https://doi.org/10.12677/acm.2024.14102826

参考文献

[1] Shah, N.P., Bhatia, R., Altman, J.K., Amaya, M., Begna, K.H., Berman, E., et al. (2024) Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22, 43-69. [Google Scholar] [CrossRef] [PubMed]
[2] Jabbour, E. and Kantarjian, H. (2022) Chronic Myeloid Leukemia: 2022 Update on Diagnosis, Therapy, and Monitoring. American Journal of Hematology, 97, 1236-1256. [Google Scholar] [CrossRef] [PubMed]
[3] Senapati, J., Sasaki, K., Issa, G.C., Lipton, J.H., Radich, J.P., Jabbour, E., et al. (2023) Management of Chronic Myeloid Leukemia in 2023—Common Ground and Common Sense. Blood Cancer Journal, 13, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
[4] Sun, J., Hu, R., Han, M., Tan, Y., Xie, M., Gao, S., et al. (2024) Mechanisms Underlying Therapeutic Resistance of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. International Journal of Biological Sciences, 20, 175-181. [Google Scholar] [CrossRef] [PubMed]
[5] Hochhaus, A., Larson, R.A., Guilhot, F., Radich, J.P., Branford, S., Hughes, T.P., et al. (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine, 376, 917-927. [Google Scholar] [CrossRef] [PubMed]
[6] Deininger, M.W., Kopecky, K.J., Radich, J.P., Kamel-Reid, S., Stock, W., Paietta, E., et al. (2013) Imatinib 800 Mg Daily Induces Deeper Molecular Responses than Imatinib 400 Mg Daily: Results of SWOG S0325, an Intergroup Randomized Phase II Trial in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia. British Journal of Haematology, 164, 223-232. [Google Scholar] [CrossRef] [PubMed]
[7] Cheng, F., Zeng, F., Li, Q., Cui, Z., Chen, Y., Li, W., et al. (2022) Imatinib Dose Optimization Based on Therapeutic Drug Monitoring in Chinese Patients with Chronic-Phase Chronic Myeloid Leukemia. Cancer, 128, 3951-3958. [Google Scholar] [CrossRef] [PubMed]
[8] Fachi, M.M., Tonin, F.S., Leonart, L.P., Aguiar, K.S., Lenzi, L., Figueiredo, B.C., et al. (2018) Comparative Efficacy and Safety of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia: A Systematic Review and Network Meta-analysis. European Journal of Cancer, 104, 9-20. [Google Scholar] [CrossRef] [PubMed]
[9] Vener, C., Banzi, R., Ambrogi, F., Ferrero, A., Saglio, G., Pravettoni, G., et al. (2020) First-Line Imatinib vs Second-and Third-Generation TKIs for Chronic-Phase CML: A Systematic Review and Meta-Analysis. Blood Advances, 4, 2723-2735. [Google Scholar] [CrossRef] [PubMed]
[10] Braun, T.P., Eide, C.A. and Druker, B.J. (2020) Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell, 37, 530-542. [Google Scholar] [CrossRef] [PubMed]
[11] García-Gutiérrez, V., Breccia, M., Jabbour, E., Mauro, M. and Cortes, J.E. (2022) A Clinician Perspective on the Treatment of Chronic Myeloid Leukemia in the Chronic Phase. Journal of Hematology & Oncology, 15, Article No. 90. [Google Scholar] [CrossRef] [PubMed]
[12] Nekoukar, Z., Moghimi, M. and Salehifar, E. (2021) A Narrative Review on Adverse Effects of Dasatinib with a Focus on Pharmacotherapy of Dasatinib-Induced Pulmonary Toxicities. BLOOD RESEARCH, 56, 229-242. [Google Scholar] [CrossRef] [PubMed]
[13] Cortes, J.E., Jiang, Q., Wang, J., Weng, J., Zhu, H., Liu, X., et al. (2020) Dasatinib vs. Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: The Dascern Randomized Study. Leukemia, 34, 2064-2073. [Google Scholar] [CrossRef] [PubMed]
[14] Cortes, J.E., Jiang, Q., Wang, J., Weng, J., Zhu, H., Liu, X., et al. (2024) Treatment of Chronic-Phase Chronic Myeloid Leukemia in Patients Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from Dascern. Haematologica, 109, 3251-3260. [Google Scholar] [CrossRef] [PubMed]
[15] Hochhaus, A., Saglio, G., Hughes, T.P., Larson, R.A., Kim, D., Issaragrisil, S., et al. (2016) Long-Term Benefits and Risks of Frontline Nilotinib vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-Year Update of the Randomized Enestnd Trial. Leukemia, 30, 1044-1054. [Google Scholar] [CrossRef] [PubMed]
[16] Radich, J.P., Hochhaus, A., Masszi, T., Hellmann, A., Stentoft, J., Casares, M.T.G., et al. (2021) Treatment-Free Remission Following Frontline Nilotinib in Patients with Chronic Phase Chronic Myeloid Leukemia: 5-Year Update of the Enestfreedom Trial. Leukemia, 35, 1344-1355. [Google Scholar] [CrossRef] [PubMed]
[17] Huang, C., Lee, K., Chang, J., Tzeng, H., Huang, S., Yu, L.H., et al. (2023) Association of Nilotinib with Cardiovascular Diseases in Patients with Chronic Myelogenous Leukemia: A National Population-Based Cohort Study. The Oncologist, 29, e81-e89. [Google Scholar] [CrossRef] [PubMed]
[18] Gambacorti-Passerini, C., Brümmendorf, T.H., Abruzzese, E., Kelly, K.R., Oehler, V.G., García-Gutiérrez, V., et al. (2024) Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the BYOND Trial. Leukemia, 38, 2162-2170. [Google Scholar] [CrossRef] [PubMed]
[19] Cortes, J.E., Kantarjian, H.M., Brümmendorf, T.H., Kim, D., Turkina, A.G., Shen, Z., et al. (2011) Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Imatinib. Blood, 118, 4567-4576. [Google Scholar] [CrossRef] [PubMed]
[20] Cortes, J.E., Khoury, H.J., Kantarjian, H.M., Lipton, J.H., Kim, D., Schafhausen, P., et al. (2016) Long-Term Bosutinib for Chronic Phase Chronic Myeloid Leukemia after Failure of Imatinib Plus Dasatinib And/or Nilotinib. American Journal of Hematology, 91, 1206-1214. [Google Scholar] [CrossRef] [PubMed]
[21] Luo, H., Quan, H., Xie, C., Xu, Y., Fu, L. and Lou, L. (2010) HH-GV-678, a Novel Selective Inhibitor of BCR-ABL, Outperforms Imatinib and Effectively Overrides Imatinib Resistance. Leukemia, 24, 1807-1809. [Google Scholar] [CrossRef] [PubMed]
[22] Yang, Y., Liu, Y., Sun, H., Meng, L., Lin, H., Chen, C., et al. (2024) Safety and Efficacy of Flumatinib as Later-Line Therapy in Patients with Chronic Myeloid Leukemia. Haematologica. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, L., Meng, L., Liu, B., Zhang, Y., Zhu, H., Cui, J., et al. (2021) Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-Label, Multi-Center Festnd Study. Clinical Cancer Research, 27, 70-77. [Google Scholar] [CrossRef] [PubMed]
[24] Kwak, J., Kim, S., Oh, S.J., Zang, D.Y., Kim, H., Kim, J., et al. (2017) Phase III Clinical Trial (RERISE Study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Cancer Research, 23, 7180-7188. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J.-Y., Sohn, S.-K., et al. (2014) Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL1 Tyrosine Kinase Inhibitors. Haematologica, 99, 1191-1196. [Google Scholar] [CrossRef] [PubMed]
[26] Noh, H., Jung, S.Y., Kwak, J., Kim, S., Oh, S.J., Zang, D.Y., et al. (2018) Determination of a Radotinib Dosage Regimen Based on Dose-Response Relationships for the Treatment of Newly Diagnosed Patients with Chronic Myeloid Leukemia. Cancer Medicine, 7, 1766-1773. [Google Scholar] [CrossRef] [PubMed]
[27] Claudiani, S., Chughtai, F., Khan, A., Hayden, C., Fernando, F., Khorashad, J., et al. (2024) Long-Term Outcomes after Upfront Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Managing Intolerance and Resistance. Leukemia, 38, 796-802. [Google Scholar] [CrossRef] [PubMed]
[28] Alves, R., Gonçalves, A.C., Rutella, S., Almeida, A.M., De Las Rivas, J., Trougakos, I.P., et al. (2021) Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers, 13, Article 4820. [Google Scholar] [CrossRef] [PubMed]
[29] Cortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., et al. (2021) Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. Blood, 138, 2042-2050. [Google Scholar] [CrossRef] [PubMed]
[30] Kantarjian, H.M., Chifotides, H.T., Haddad, F.G., Short, N.J., Loghavi, S. and Jabbour, E. (2024) Ponatinib-Review of Historical Development, Current Status, and Future Research. American Journal of Hematology, 99, 1576-1585. [Google Scholar] [CrossRef] [PubMed]
[31] Cortes, J.E., Kim, D., Pinilla-Ibarz, J., le Coutre, P.D., Paquette, R., Chuah, C., et al. (2018) Ponatinib Efficacy and Safety in Philadelphia Chromosome-Positive Leukemia: Final 5-Year Results of the Phase 2 PACE Trial. Blood, 132, 393-404. [Google Scholar] [CrossRef] [PubMed]
[32] Berman, E. (2022) How I Treat Chronic-Phase Chronic Myelogenous Leukemia. Blood, 139, 3138-3147. [Google Scholar] [CrossRef] [PubMed]
[33] Jiang, Q., Li, Z., Qin, Y., Li, W., Xu, N., Liu, B., et al. (2022) Olverembatinib (HQP1351), a Well-Tolerated and Effective Tyrosine Kinase Inhibitor for Patients with T315i-Mutated Chronic Myeloid Leukemia: Results of an Open-Label, Multicenter Phase 1/2 Trial. Journal of Hematology & Oncology, 15, Article No. 113. [Google Scholar] [CrossRef] [PubMed]
[34] Dhillon, S. (2022) Olverembatinib: First Approval. Drugs, 82, 469-475. [Google Scholar] [CrossRef] [PubMed]
[35] Hochhaus, A., Wang, J., Kim, D., Kim, D.D.H., Mayer, J., Goh, Y., et al. (2024) Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. New England Journal of Medicine, 391, 885-898. [Google Scholar] [CrossRef] [PubMed]
[36] Cortes, J.E., Sasaki, K., Kim, D., Hughes, T.P., Etienne, G., Mauro, M.J., et al. (2024) Asciminib Monotherapy in Patients with Chronic-Phase Chronic Myeloid Leukemia with the T315I Mutation after ≥1 Prior Tyrosine Kinase Inhibitor: 2-Year Follow-up Results. Leukemia, 38, 1522-1533. [Google Scholar] [CrossRef] [PubMed]
[37] Réa, D., Mauro, M.J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., et al. (2021) A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML after 2 or More Prior TKIs. Blood, 138, 2031-2041. [Google Scholar] [CrossRef] [PubMed]
[38] Yeung, D.T., Shanmuganathan, N., Reynolds, J., Branford, S., Walia, M., Yong, A.S., et al. (2024) Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study. Blood Journal. [Google Scholar] [CrossRef] [PubMed]
[39] Mian, A.A., Rafiei, A., Haberbosch, I., Zeifman, A., Titov, I., Stroylov, V., et al. (2014) PF-114, a Potent and Selective Inhibitor of Native and Mutated BCR/ABL Is Active against Philadelphia Chromosome-Positive (Ph+) Leukemias Harboring the T315I Mutation. Leukemia, 29, 1104-1114. [Google Scholar] [CrossRef] [PubMed]
[40] Ivanova, E., Tatarskiy, V., Yastrebova, M., Khamidullina, A., Shunaev, A., Kalinina, A., et al. (2019) PF-114, a Novel Selective Inhibitor of BCR-ABL Tyrosine Kinase, Is a Potent Inducer of Apoptosis in Chronic Myelogenous Leukemia Cells. International Journal of Oncology, 55, 289-297. [Google Scholar] [CrossRef] [PubMed]
[41] Shi, Y., Jiang, Q., Li, L., Jiang, S., Yan, T., Zheng, C., et al. (2023) Tgrx-678, a Novel Allosteric Inhibitor of BCR-ABL1, Demonstrates Preclinical Anti-Leukemia Activity, High Oral Bioavailability and Synergism with Ponatinib to Suppress the Highly Resistant Compound Mutations. Blood, 142, 2807. [Google Scholar] [CrossRef] 

为你推荐